January 26th, 2012

Zoledronic Acid Controversy in Breast Cancer Continues

By

A growing body of evidence backs the contention that bisphosphonates can improve survival in breast cancer patients with low estrogen levels. The results of three studies of bisphosphonates in this setting presented at the recent San Antonio Breast Cancer Symposium (SABCS) support the low estrogen hypothesis, whereas interim results of a fourth trial presented there were negative. Some experts, including James Ingle, MD, a professor of oncology at the Mayo Clinic in Rochester, who served as a discussant for the trials at SABCS, consider there to be “mounting evidence ... that bisphosphonates will become established as efficacious in adjuvant therapy of postmenopausal women with early-stage breast cancer.”

Pharmacy Practice News, by Kate O’Rourke, 01/25/2012

Tags: Breast Cancer, Cancer, Dr. James Ingle, estrogen levels, Mayo Clinic Rochester, oncology, Research, San Antonio Breast Cancer Symposium

Contact Us · Privacy Policy